Pharmacogenomics is heating up as excitement grows around artificial intelligence tools in genomics. Check out five startups gunning to meet the soaring demand.

Around 95% of the population has a gene variant that affects how we respond to at least one drug, often based on how well our bodies break down the molecule. If the drug is broken down by a patient’s body more slowly than normal, for example, the patient can experience more side effects than others.

For this reason, pharmacogenomics is a critical component of precision medicine, which aims to provide safe and effective medications tailored to a patient’s genome.

The global market for pharmacogenomics was worth $7.6 billion in 2024 and is expected to grow by 8.1% per year to $12.4 billion by 2030. At the same time, the market

See Full Page